

CASE LD0275A CIP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF  
SALVATI ET AL.

APPLICATION NO: 10/672,850

FILED: SEPTEMBER 26, 2003

FOR: PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE  
THEREOF FOR THE TREATMENT OF PROLIFERATIVE  
DISORDERS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER

Sir:

Bristol-Myers Squibb Company, a Delaware corporation, having a place of business at Lawrenceville-Princeton Road, Princeton, NJ 08543-4000, represents that it is the assignee and owner of the entire interest in the above-identified application by virtue of an assignment which was recorded in the United States Patent and Trademark Office on November 14, 2003 at Reel/Frame 014133/0892.

Bristol-Myers Squibb Company hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154-156 and §173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending **Application No. 10/396,197** filed March 25, 2003. Said Application No. 10/396,197 is also assigned to Bristol-Myers Squibb Company by virtue of an assignment which was recorded in the United States Patent and Trademark Office on June 17, 2003 at Reel/Frame 013739/0939.

Bristol-Myers Squibb Company hereby agrees that any patent granted on the above-identified application shall be enforceable only for and during such period that it and any patent granted on Application No. 10/396,197 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

05/12/2005 HMARZ11 00000009 193880 10672850


01 FC:1814 130.00 DA

In making the above disclaimer, Bristol-Myers Squibb Company does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 USC §154-156 and §173 of any patent granted on Application No. 10/396,197, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.


A terminal disclaimer fee under 37 CFR §1.20(d) is included.

Signed this 9th day of May, 2005 by the undersigned attorney of record.

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-4741



Elliott Kersen  
Attorney for Applicants  
Reg. No. 32,705



CASE LD0275A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Elliott Korsen  
Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
May 9, 2005  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SALVATI ET AL.

APPLICATION NO: 10/672,850

FILED: SEPTEMBER 26, 2003

FOR: PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE  
THEREOF FOR THE TREATMENT OF PROLIFERATIVE  
DISORDERS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

FEE LETTER

Sir:

Enclosed herewith is a Terminal Disclaimer in the above-identified application.

The Commissioner is hereby authorized to charge the \$130 fee under 37 CFR §1.20(d) and any additional fees that may be required to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is here enclosed.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-4741  
Date: May 9, 2005

\_\_\_\_\_  
Elliott Korsen  
Attorney for Applicants  
Reg. No. 32,705